Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences
Resectable non-small cell lung cancer (NSCLC) continues to pose significant challenges with high recurrence and mortality rates, despite traditional platinum-based chemotherapy yielding only an approximate 5% improvement in 5-year overall survival when administered preoperatively or postoperatively....
Saved in:
| Main Authors: | Thoma’ Dario Clementi, Francesca Colonese, Stefania Canova, Maria Ida Abbate, Luca Sala, Francesco Petrella, Gabriele Giuseppe Pagliari, Diego Luigi Cortinovis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/7/397 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01) -
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
by: Belén Sierra Rodero, et al.
Published: (2025-12-01) -
Blocking copper transporter protein-dependent drug efflux with albumin-encapsulated Pt(IV) for synergistically enhanced chemo-immunotherapy
by: Man Fang, et al.
Published: (2025-03-01) -
Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer
by: Liling Huang, et al.
Published: (2025-05-01) -
Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)